Urology
Volume 74, Issue 1 , Pages 82-87 , July 2009

α-Blocker Use Is Associated With Decreased Risk of Sexual Dysfunction

  • Rajeev Kumar

      Affiliations

    • Department of Urology, All India Institute of Medical Sciences, New Delhi, India
    • ,
  • Ajay Nehra

      Affiliations

    • Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota
    • Corresponding Author InformationReprint requests: Ajay Nehra, M.D., Department of Urology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905
    • ,
  • Debra J. Jacobson

      Affiliations

    • Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Michaela E. McGree

      Affiliations

    • Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Naomi M. Gades

      Affiliations

    • Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Michael M. Lieber

      Affiliations

    • Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Steven J. Jacobsen

      Affiliations

    • Southern California Permanente Medical Group, Pasadena, California
    • ,
  • Jennifer L. St. Sauver

      Affiliations

    • Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota

Received 18 August 2008 ,Accepted 18 December 2008.

References 

  1. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the “Cologne Male Survey.”. Int J Impot Res. 2000;12:305–311
  2. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637–649
  3. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 2006;97(suppl 2):23–28
  4. van Moorselaar RJ, Hartung R, Emberton M, et al. ALF-ONE Study Group Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int. 2005;95:603–608
  5. Jacobsen SJ, Guess HA, Panser L, et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med. 1993;2:729–735
  6. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA. 1993;270:860–864
  7. O'Leary MP, Rhodes T, Girman CJ, et al. Distribution of the brief male sexual inventory in community men. Int J Impot Res. 2003;15:185–191
  8. Burke JP, Jacobson DJ, McGree ME, et al. Diabetes and sexual dysfunction: results from the Olmsted County Study of Urinary Symptoms and Health Status Among Men. J Urol. 2007;177:1438–1442
  9. Barry MJ, Fowler FJ, O'Leary MP, et al. Measurement Committee of the American Urological Association The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol. 1992;148:1558–1563
  10. Schoenfeld D. Chi-squared goodness-of-fit tests for the proportional hazards regression model. Biometrika. 1980;67:145–153
  11. Costabile RA, Steers WD. How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia?. J Sex Med. 2006;3:676–681
  12. Goldstein I. Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction. Int J Impot Res. 2000;12(suppl 1):S75–S80
  13. Demir O, Murat N, Aslan G, et al. Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction. J Urol. 2006;175:22345–22349
  14. Brookes ST, Donovan JL, Peters TJ. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ. 2002;324:1059–1061
  15. Kirby RS, O'Leary MP, Carson C. Efficacy of extended-release doxazosin and doxazosin standard inpatients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int. 2005;95:103–109
  16. Höfner K, Claes H, De Reijke TM, et al. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36:335–341

 This project was supported by research grants from the Public Health Service, National Institutes of Health (grants DK58859, AR30582, and 1Ul1 RR024150-01), and Merck Research Laboratories.

PII: S0090-4295(09)00269-6

doi: 10.1016/j.urology.2008.12.080

Urology
Volume 74, Issue 1 , Pages 82-87 , July 2009

Article Tools